In the high-dose I.P. subgroup, the ORR increased to 28.6%, with sustained tumor remission beyond 5 months in responders, highlighting I.P. administration as a promising route for CEA CAR T delivery in solid tumors [59]. Here, CEACAM5 is linked to neoplasm.